FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125765080> ?p ?o ?g. }

• W2125765080 endingPage "9" @default.
• W2125765080 startingPage "3670" @default.
• W2125765080 abstract "We have demonstrated previously an improved therapeutic index for oral 5-iodo-2-deoxypyrimidinone-2'-deoxyribose (IPdR) compared with oral and continuous infusion of 5-iodo-2'-deoxyuridine (IUdR) as a radiosensitizing agent using three different human tumor xenografts in athymic mice. IPdR is a prodrug that is efficiently converted to IUdR by a hepatic aldehyde oxidase, resulting in high IPdR and IUdR plasma levels in mice for > or =1 h after p.o. IPdR. Athymic mice tolerated oral IPdR at up to 1500 mg/kg/day given four times per day for 6-14 days without significant systemic toxicities. In anticipation of an investigational new drug application for the first clinical Phase I and pharmacology study of oral IPdR in humans, we studied the drug pharmacokinetics and host toxicities in two non-rodent, animal species. For the IPdR systemic toxicity and toxicology study, twenty-four male or female ferrets were randomly assigned to four IPdR dosage groups receiving 0, 15, 150, and 1500 mg/kg/day by oral gavage x 14 days prior to sacrifice on study day 15. All ferrets survived the 14-day treatment. Ferrets receiving 1500 mg/kg/day showed observable systemic toxicities with diarrhea, emesis, weight loss, and decreased motor activity beginning at days 5-8 of the 14-day schedule. Overall, both male and female ferrets receiving IPdR at 1500 mg/kg/day experienced significant weight loss (9 and 19%, respectively) compared with controls after the 14-day treatment. No weight loss or other systemic toxicities were observed in other IPdR dosage groups. Grossly, no anatomical lesions were noted at complete necropsy, although liver weights were increased in both male and female ferrets in the two higher IPdR dosage groups. Histologically, IPdR-treated animals showed dose-dependent microscopic changes in liver consisting of minimal to moderate cytoplasmic vacuolation of hepatocytes, which either occurred in the periportal area (high dosage group) or diffusely throughout the liver (lower dosage groups). Female ferrets in the highest IPdR dose group also showed decreased kidney and uterus weights at autopsy without any associated histological changes. No histological changes were found in central nervous system tissues. No significant abnormalities in blood cell counts, liver function tests, kidney function tests, or urinalysis were noted. Hepatic aldehyde oxidase activity was decreased to approximately 50 and 30% of control ferrets in the two higher IPdR dosage groups, respectively, after the 14-day treatment period. The % IUdR-DNA incorporation in ferret bone marrow at the completion of IPdR treatment was < or =0.05% in the two lower dosage groups and approximately 2% in the 1500 mg/kg/day dosage group. The % IUdR-DNA in normal liver was < or =0.05% in all IPdR dosage groups. In a pharmacokinetic study in four Rhesus monkeys, we determined the plasma concentrations of IPdR after a single i.v. bolus of 50 mg/kg over 20 min. Using a two-compartment model to fit the plasma pharmacokinetic data, we found that IPdR was cleared in these non-human primates in a biexponential manner with an initial rapid distributive phase (mean T1/2alpha = 6.5 min), followed by an elimination phase with a mean T1/2 of 63 min. The mean maximum plasma concentration of IPdR was 124+/-43 microM with a mean total body clearance of 1.75+/-0.95 l/h/kg. IPdR was below detection (<0.5 microM) in the cerebrospinal fluid. We conclude that there are dose-limiting systemic toxicities to a 14-day schedule of p.o. IPdR at 1500 mg/kg/day in ferrets that were not found previously in athymic mice. However, no significant hematological, biochemical, or histopathological changes were found. Hepatic aldehyde oxidase activity was reduced in a dose-dependent in ferret liver, suggesting partial enzyme saturation by this IPdR schedule. The plasma pharmacokinetic profile in Rhesus monkeys showing biexponential clearance is similar to our published data in athymic mice. These data are being applied" @default.
• W2125765080 created "2016-06-24" @default.
• W2125765080 creator A5007632399 @default.
• W2125765080 creator A5024249524 @default.
• W2125765080 creator A5035958980 @default.
• W2125765080 creator A5065909085 @default.
• W2125765080 creator A5070678501 @default.
• W2125765080 creator A5073623971 @default.
• W2125765080 creator A5075652515 @default.
• W2125765080 creator A5079299908 @default.
• W2125765080 creator A5089798708 @default.
• W2125765080 date "2000-09-01" @default.
• W2125765080 modified "2023-09-24" @default.
• W2125765080 title "Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design." @default.
• W2125765080 cites W1514487637 @default.
• W2125765080 cites W1517575086 @default.
• W2125765080 cites W1577985842 @default.
• W2125765080 cites W1606145701 @default.
• W2125765080 cites W1654879433 @default.
• W2125765080 cites W1863874903 @default.
• W2125765080 cites W1923403766 @default.
• W2125765080 cites W1931275626 @default.
• W2125765080 cites W1965987309 @default.
• W2125765080 cites W1972751666 @default.
• W2125765080 cites W1998894350 @default.
• W2125765080 cites W2006425047 @default.
• W2125765080 cites W2010687829 @default.
• W2125765080 cites W2027124686 @default.
• W2125765080 cites W2041310709 @default.
• W2125765080 cites W2042697384 @default.
• W2125765080 cites W2048086887 @default.
• W2125765080 cites W2054158070 @default.
• W2125765080 cites W2076077165 @default.
• W2125765080 cites W2084256023 @default.
• W2125765080 cites W2092235777 @default.
• W2125765080 cites W2125789476 @default.
• W2125765080 cites W2126125019 @default.
• W2125765080 cites W2158478305 @default.
• W2125765080 cites W2167836234 @default.
• W2125765080 cites W2231502604 @default.
• W2125765080 cites W2265797396 @default.
• W2125765080 cites W2431724685 @default.
• W2125765080 cites W2464463623 @default.
• W2125765080 cites W2605040850 @default.
• W2125765080 cites W2955504961 @default.
• W2125765080 cites W2128638452 @default.
• W2125765080 cites W2130929934 @default.
• W2125765080 cites W2408890315 @default.
• W2125765080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10999760" @default.
• W2125765080 hasPublicationYear "2000" @default.
• W2125765080 type Work @default.
• W2125765080 sameAs 2125765080 @default.
• W2125765080 citedByCount "8" @default.
• W2125765080 countsByYear W21257650802019 @default.
• W2125765080 countsByYear W21257650802023 @default.
• W2125765080 crossrefType "journal-article" @default.
• W2125765080 hasAuthorship W2125765080A5007632399 @default.
• W2125765080 hasAuthorship W2125765080A5024249524 @default.
• W2125765080 hasAuthorship W2125765080A5035958980 @default.
• W2125765080 hasAuthorship W2125765080A5065909085 @default.
• W2125765080 hasAuthorship W2125765080A5070678501 @default.
• W2125765080 hasAuthorship W2125765080A5073623971 @default.
• W2125765080 hasAuthorship W2125765080A5075652515 @default.
• W2125765080 hasAuthorship W2125765080A5079299908 @default.
• W2125765080 hasAuthorship W2125765080A5089798708 @default.
• W2125765080 hasConcept C108215921 @default.
• W2125765080 hasConcept C112705442 @default.
• W2125765080 hasConcept C126322002 @default.
• W2125765080 hasConcept C181199279 @default.
• W2125765080 hasConcept C2777056448 @default.
• W2125765080 hasConcept C2778102346 @default.
• W2125765080 hasConcept C2779840689 @default.
• W2125765080 hasConcept C2780035454 @default.
• W2125765080 hasConcept C29730261 @default.
• W2125765080 hasConcept C55493867 @default.
• W2125765080 hasConcept C71924100 @default.
• W2125765080 hasConcept C86803240 @default.
• W2125765080 hasConcept C98274493 @default.
• W2125765080 hasConceptScore W2125765080C108215921 @default.
• W2125765080 hasConceptScore W2125765080C112705442 @default.
• W2125765080 hasConceptScore W2125765080C126322002 @default.
• W2125765080 hasConceptScore W2125765080C181199279 @default.
• W2125765080 hasConceptScore W2125765080C2777056448 @default.
• W2125765080 hasConceptScore W2125765080C2778102346 @default.
• W2125765080 hasConceptScore W2125765080C2779840689 @default.
• W2125765080 hasConceptScore W2125765080C2780035454 @default.
• W2125765080 hasConceptScore W2125765080C29730261 @default.
• W2125765080 hasConceptScore W2125765080C55493867 @default.
• W2125765080 hasConceptScore W2125765080C71924100 @default.
• W2125765080 hasConceptScore W2125765080C86803240 @default.
• W2125765080 hasConceptScore W2125765080C98274493 @default.
• W2125765080 hasIssue "9" @default.
• W2125765080 hasLocation W21257650801 @default.
• W2125765080 hasOpenAccess W2125765080 @default.
• W2125765080 hasPrimaryLocation W21257650801 @default.
• W2125765080 hasRelatedWork W1518449587 @default.
• W2125765080 hasRelatedWork W1870547027 @default.
• W2125765080 hasRelatedWork W1998540654 @default.

• next